Multidisciplinary Association for Psychedelic Studies (MAPS)

PARTNER HIGHLIGHT

Each day, we lose 22 veterans to PTSD-related suicide. First responders and victims of domestic violence struggle silently with the traumas they’ve endured. Mental illness affects nearly one-third of people experiencing homelessness. Conventional treatments have failed many who have sought help. We must do better for our veterans and all who suffer.

For over 35 years, the Multidisciplinary Association for Psychedelic Studies (MAPS) has been a leader in researching safe, legal and beneficial opportunities for the careful use of psychedelics as a medicine for treatment-resistant PTSD, depression and addiction. At last, MDMAAssisted Therapy, an emerging breakthrough treatment, is nearing the end of clinical trials and potential FDA approval.

MAPS is actively recruiting and training therapists, particularly therapists of color, to ensure that patients undergoing treatment can trust and relate to the people guiding them towards healing and recovery.

With 68% of study participants no longer diagnosed with PTSD 12 months following the treatment, it’s clear that help is on the way. To explore the published results and follow them to the finish line, visit maps.org.